Interestingly, when leukemia returned, analysis was performed and residual AML cells continued to express CD33/123, thus concluding that these cells did not develop the resistance mechanisms employed as previously described in CD19 CAR immunotherapy (92). Here, CD33 is linked to acute myeloid leukemia.